Selected References:
- Aharon D. 1998. Pharmacology of leukotriene receptor antagonist. American Journal of Respirator Critical Care Medicine, 157; 214-219.
- Bakhireva LN, et al. 2007. Safety of leukotriene receptor antagonists in pregnancy. Journal of Allergy and Clinical Immunology, 119; 618-625.
- Cavero-Carbonell C, et al. 2017. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res, 109(6):452-459.
- Datta P, et al. 2017. Transfer of montelukast into human milk during lactation. Breastfeed Med, 12:54-57. Hatakeyama S, et al. 2022. The safety of pranlukast and montelukast during the first trimester of pregnancy: a prospective, two-centered cohort study in Japan. Congenit Anom (Kyoto), 62(4):161-168.
- Merck Sharp & Dohme Corp. 2022. Singulair product labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c166755-7711-4df9-d689-8836a1a70885
- Nelsen LM, et al. 2012. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol, 129(1):251-254.e1-6.
- Sarkar M, et al. 2009. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes Eur J Clin Pharmacol, 65(12):1259-1264.
- The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol, 84:475-480.
